GlassScriptPhysician profile
Bruna Pellini Ferreira
NPI 1790199719
$157,748.91
in general payments reported to CMS, 2019-2025
25 companies · $70K in 2025
The $70K reported for 2025 was more than what 97% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2021: $3,450 · 2022: $10K · 2023: $33K · 2024: $41K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $97K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $12K · Honoraria: $4,750 · Food and Beverage: $4,448 · Education: $52.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $96,665.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,245.00 |
| Travel and Lodging | $12,190.99 |
| Honoraria | $4,750.00 |
| Food and Beverage | $4,447.67 |
| Education | $52.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $39,889.61 | 2021-2025 | Tagrisso, Enhertu, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $23,392.25 | 2022-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $21,593.35 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $17,202.08 | 2019-2024 | Opdivo |
| Eli Lilly and Company | $12,225.00 | 2025 | |
| Gilead Sciences, INC. | $11,924.26 | 2023-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $7,350.00 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,242.85 | 2024-2025 | |
| Amgen INC. | $4,000.00 | 2025 | Imdelltra (Amg757) |
| Regeneron Pharmaceuticals, INC. | $2,754.00 | 2025 | Libtayo |
| Life Technologies Corporation | $2,500.00 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $2,349.69 | 2024 | |
| Foundation Medicine, INC. | $2,190.78 | 2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Caris Mpi, INC. | $1,500.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $1,478.84 | 2024-2025 | Rybrevant |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.00 | 2025 | |
| Genentech USA, INC. | $364.48 | 2019-2025 | Tecentriq |
| Janssen Biotech, INC. | $259.18 | 2025 | Rybrevant |
| Genmab U.S., INC. | $218.36 | 2023-2025 | |
| Astrazeneca Uk Limited | $157.79 | 2024 | |
| Genzyme Corporation | $122.21 | 2019 | |
| Jazz Pharmaceuticals INC. | $93.35 | 2024 | |
| Davol INC. | $79.83 | 2025 | Progel Applicator Spray Tips |
| Lilly USA, LLC | $58.50 | 2019 | |
| Daiichi Sankyo INC. | $52.50 | 2024 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruna Pellini Ferreira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.